83 Results for "

antibody dependent cellular cytotoxicity

" in MedChemExpress (MCE) Product Catalog:
Products (83)

83 Results for "antibody dependent cellular cytotoxicity" in MCE Product Catalog:

3
Trastuzumab vedotin
Trastuzumab vedotin
0 Images
3 Cited Publications
Cat. No.: HY-164992
Synonyms: MRG002; Trastuzumab MMAE
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
loading...
    loading...
View All Sizes
1
Isatuximab
Isatuximab
0 Images
1 Cited Publications
Cat. No.: HY-P9976
CAS No.: 1461640-62-9
Synonyms: ch38SB19; hu38SB19; SAR-650984

Target:  

CD38 Apoptosis

Research Areas:  

Cancer

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .
loading...
    loading...
View All Sizes
1
Cadonilimab
Cadonilimab
0 Images
1 Cited Publications
Cat. No.: HY-P99117
CAS No.: 2394841-59-7
Synonyms: AK104

Target:  

PD-1/PD-L1 CTLA-4

Research Areas:  

Inflammation/Immunology Cancer

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .
loading...
    loading...
View All Sizes
1
Codrituzumab
Codrituzumab
0 Images
1 Cited Publications
Cat. No.: HY-P99013
CAS No.: 1365267-33-9
Synonyms: GC33; RO5137382
Target:  

Glycoprotein VI

Research Areas:  

Cancer

Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
loading...
    loading...
View All Sizes
1
Cusatuzumab
Cusatuzumab
0 Images
1 Cited Publications
Cat. No.: HY-P99014
CAS No.: 1864871-20-4
Synonyms: ARGX-110

Target:  

Fc Receptor (FcR) NF-κB

Research Areas:  

Inflammation/Immunology Cancer

Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
loading...
    loading...
View All Sizes
1
Anbenitamab
Anbenitamab
0 Images
1 Cited Publications
Cat. No.: HY-P99437
CAS No.: 2367012-88-0
Synonyms: KN-026

Target:  

EGFR

Research Areas:  

Cancer

Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer .
loading...
    loading...
View All Sizes
1
Isatuximab (anti-CD38)
Isatuximab (anti-CD38)
0 Images
1 Cited Publications
Cat. No.: HY-P9976A
CAS No.: 1461640-62-9

Target:  

CD38 Apoptosis

Research Areas:  

Cancer

Isatuximab (anti-CD38) is a monoclonal antibody that targets the transmembrane receptor and extracellular enzyme CD38, a protein highly expressed in hematological malignancies, including multiple myeloma. Isatuximab (anti-CD38) exhibits anti-tumor activity through multiple biological mechanisms, including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cell phagocytosis, and non-crosslinking direct induction of apoptosis. Isatuximab (anti-CD38) also directly inhibits the extracellular enzyme activity of CD38, which is related to many cellular functions .
loading...
    loading...
View All Sizes
1
Mogamulizumab
Mogamulizumab
0 Images
1 Cited Publications
Cat. No.: HY-P99253
CAS No.: 1159266-37-1
Synonyms: KW-0761

Target:  

CCR

Research Areas:  

Inflammation/Immunology Cancer

Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .
loading...
    loading...
View All Sizes
1
Galiximab
Galiximab
0 Images
1 Cited Publications
Cat. No.: HY-P99293
CAS No.: 357613-77-5
Synonyms: IDEC 114; Anti-Human CD80 Recombinant antibody
Target:  

CD28 Apoptosis

Research Areas:  

Cancer

Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .
loading...
    loading...
View All Sizes
1
XmAb 5592
XmAb 5592
0 Images
1 Cited Publications
Cat. No.: HY-P99381
CAS No.: 1221901-33-2

Target:  

Transmembrane Glycoprotein

Research Areas:  

Cancer

XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .
loading...
    loading...
View All Sizes
Surovatamig
Surovatamig
0 Images
Cat. No.: HY-P991028
CAS No.: 2892667-02-4
Synonyms: AZD0486; TNB-486

Target:  

CD3 CD19 Interleukin Related TNF Receptor IFNAR

Research Areas:  

Cancer

Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma .
loading...
    loading...
View All Sizes
Enavatuzumab
Enavatuzumab
0 Images
Cat. No.: HY-P99361
CAS No.: 1062149-33-0
Synonyms: PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference antibody (enavatuzumab)

Target:  

TNF Receptor

Research Areas:  

Cancer

Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
loading...
    loading...
View All Sizes
Necitumumab
Necitumumab
0 Images
Cat. No.: HY-P9964
CAS No.: 906805-06-9
Synonyms: 11F8; IMC-11F8; LY3012211

Target:  

EGFR

Research Areas:  

Cancer

Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .
loading...
    loading...
View All Sizes
Inebilizumab (FUT8-KO)
Inebilizumab (FUT8-KO)
0 Images
Cat. No.: HY-P99113A

Target:  

CD19

Research Areas:  

Neurological Disease Inflammation/Immunology

Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica .
loading...
    loading...
View All Sizes
Ficerafusp alfa
Ficerafusp alfa
0 Images
Cat. No.: HY-P990957
CAS No.: 2764727-44-6
Synonyms: BCA-101; FMAB2

Target:  

EGFR TGF-beta/Smad

Research Areas:  

Inflammation/Immunology Cancer

Ficerafusp alfa (BCA-101) is a bispecific antibody targeting EGFR and TGFβ, with a Kd of 2.58 nM against EGFR and a Kd of 61.3 nM against TGFβ1. Ficerafusp alfa binds to EGFR, inhibits EGFR phosphorylation, blocks EGF-dependent cell proliferation, and mediates antibody-dependent cellular cytotoxicity against EGFR-positive tumor cells. Ficerafusp alfa sequesters TGFβ via its TGFβRII ECD domain, neutralizes the activity of TGFβ and TGFβ1, and blocks TGFβ-dependent processes, including epithelial-mesenchymal transition, cell invasion, and differentiation of inducible regulatory T cells. Ficerafusp alfa is applicable to research related to head and neck squamous cell carcinoma, advanced solid tumors, squamous non-small cell lung cancer, anal squamous cell carcinoma, colorectal cancer, and pancreatic cancer .
loading...
    loading...
View All Sizes
Lintuzumab
Lintuzumab
0 Images
Cat. No.: HY-P9983
CAS No.: 166089-32-3
Synonyms: SGN-33; HuM-195; GLK-33 antibody

Target:  

Transmembrane Glycoprotein Radionuclide-Drug Conjugates (RDCs)

Research Areas:  

Inflammation/Immunology

Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .
loading...
    loading...
View All Sizes
Duligotuzumab
Duligotuzumab
0 Images
Cat. No.: HY-P99866
CAS No.: 1314238-96-4
Synonyms: MEHD-7945A; RG 7597

Target:  

EGFR Akt p38 MAPK Apoptosis

Research Areas:  

Cancer

Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody targeting EGFR. Duligotuzumab blocks the binding of ligands to these two receptors, inhibits downstream HER/ErbB, AKT and MAPK signaling pathways, induces antibody-dependent cellular cytotoxicity, reduces the proliferation and migration abilities of cancer cells, promotes apoptosis, exerts radiosensitizing effects, and reverses EGFR resistance in cancer cells. Duligotuzumab can be used in tumor-related research .
loading...
    loading...
View All Sizes
Nesfrotamig
Nesfrotamig
0 Images
Cat. No.: HY-P991149
CAS No.: 2966936-23-0
Synonyms: YH32367; ABL105

Target:  

TNF Receptor

Research Areas:  

Cancer

Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting HER2 and 4-1BB. The Kd values of Nesfrotamig for human HER2 and human 4-1BB are 0.48 nM and 3.36 nM, respectively. By blocking tumor cell growth signals, activating HER2-dependent local 4-1BB in tumors to maintain T cell survival, and inducing NK cell-mediated antibody-dependent cellular cytotoxicity, Nesfrotamig enhances the cytotoxicity and tumor infiltration ability of immune cells. Nesfrotamig promotes the generation of tumor-specific memory T cells, drives T cell-mediated tumor lysis, exhibits significant anti-tumor efficacy against both HER2-positive and HER2-low-expressing tumors, and shows synergistic activity when combined with anti-PD-1 antibodies. In cynomolgus monkey studies, Nesfrotamig demonstrates good safety and is suitable for research related to HER2-positive and HER2-low-expressing tumors .
loading...
    loading...
View All Sizes
Fidasimtamab
Fidasimtamab
0 Images
Cat. No.: HY-P99618
CAS No.: 2377419-89-9
Synonyms: IBI-315; BH2950

Target:  

EGFR PD-1/PD-L1

Research Areas:  

Cancer

Fidasimtamab is a bispecific antibody targeting human epidermal growth factor receptor 2 (Her2) and programmed death protein 1 (PD-1), with a Ka of 3.55e-10 M for human Her2 and a Ka of 1.17e-9 M for human PD-1. Fidasimtamab cross-links Her2-positive tumor cells with PD-1-positive T cells to form immune synapses, blocks PD-1-ligand interactions, preserves antibody-dependent cellular cytotoxicity, induces gasdermin B (GSDMB)-mediated pyroptosis, and activates T cells. Fidasimtamab is applicable to relevant research on Her2-positive gastric cancer .
loading...
    loading...
View All Sizes
Tagmokitug
Tagmokitug
0 Images
Cat. No.: HY-P991061
CAS No.: 3024486-14-1
Synonyms: CHS-114; SRF-114
Target:  

CCR

Research Areas:  

Cancer

Tagmokitug (CHS-114; SRF-114) is a fully human IgG1 antibody targeting CCR8. Tagmokitug selectively binds to human CCR8 (Kd = 502 pM) and mediates the death of CCR8-expressing cells via antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. Tagmokitug selectively eliminates intratumoral regulatory T cells, induces tumor growth inhibition, remodels the tumor immune microenvironment, and promotes the differentiation of cytotoxic CD8 + T cell subsets. Tagmokitug can be used for the research of solid tumors .
loading...
    loading...
View All Sizes
Assay Types